Cost and Cost-Effectiveness Analysis of Ondansetron Versus Metoclopramide Regimens†
- 1 March 1994
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 5 (3) , 227-237
- https://doi.org/10.2165/00019053-199405030-00006
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The real costs of emesis—An economic analysis of ondansetron vs. Metoclopramide in controlling emesis in patients receiving chemotherapy for cancerEuropean Journal Of Cancer, 1993
- Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.1993
- OndansetronPharmacoEconomics, 1993
- Ondansetron: A Cost-Effective Advance in Anti-Emetic TherapyOncology, 1993
- Low dose ondansetron and dexamethasone: A cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesisClinical Oncology, 1992
- Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting.1992
- Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.Journal of Clinical Oncology, 1992
- OndansetronPharmacoEconomics, 1992
- Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.1992
- Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group studyBritish Journal of Cancer, 1992